Please login to the form below

Not currently logged in


This page shows the latest Kalydeco news and features for those working in and with pharma, biotech and healthcare.

Leiden reassures on key role at Vertex

Leiden reassures on key role at Vertex

Soon after followed the approval of the company's first CF treatment, Kalydeco, which signalled the beginning of a highly profitable franchise.

Latest news

More from news
Approximately 6 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Luckily, that plan B was waiting in the wings: Kalydeco (ivacaftor), the first ever disease-modifying treatment for cystic fibrosis gained approval in 2012. ... Jeff Leiden, Vertex CEO. The company built on its initial ‘precision medicine’ Kalydeco,

  • The Orkambi row explained The Orkambi row explained

    He says it has overpaid for Kalydeco by £400m over five years – not a ‘fair and reasonable price’. ... December 2016: NHSE approves expanded use of Kalydeco to two-to-five-year-olds in England, benefiting around 50 children.

  • The Orkambi blame game The Orkambi blame game

    price of its existing CF treatments Kalydeco and Orkambi, as well as new combination Symkevi and any subsequent products. ... an overly generous deal on Vertex’s first CF drug, Kalydeco, in 2012.

  • #OrkambiNow? #OrkambiNow?

    The US company, based in Cambridge, Massachusetts is a pioneer of groundbreaking ‘precision medicine’ drugs against cystic fibrosis Kalydeco (launched in 2012) and Orkambi (2015) and now Symkevi (2018). ... time of Kalydeco’s arrival in 2012.

  • The good, the bad and the ugly The good, the bad and the ugly

    Vertex has two - with Kalydeco sitting alongside Orkambi in an impressive respiratory portfolio.”.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Marketing strategy in complex environments

    One example of this is in  cystic fibrosis, and the advent of disease modifying agents specific towards certain genetic mutations ( Kalydeco,   Orkambi).

  • Frontera Group

    2014 Rx Club of New York. Integrated Award of Excellence - Kalydeco. ... Bronze - Kalydeco - Consumer Direct Campaign. Bronze x4 - Great People Wanted (Frontera recruitment) - Business to Business Self Promotion.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...